Skip to main content
NCBI home page
Cureus logoLink to Cureus
. 2022 Nov 22;14(11):e31808. doi: 10.7759/cureus.31808

Immunoglobulin-Induced Aseptic Meningitis in Juvenile Dermatomyositis: A Case Report

Oi Man Chan 1,✉, Chon In Kuok 2, Kwai Yu Winnie Chan 2, Hoi Man Roanna Yeung 2
Editors: Alexander Muacevic, John R Adler
PMCID: PMC9780508  PMID: 36579229

Abstract

Aseptic meningitis is a known but unusual serious adverse effect of intravenous immunoglobulin (IVIG). It usually resembles infectious meningitis, which makes its diagnosis challenging. In this report, we present the case of a five-and-a-half-year-old Chinese girl with juvenile dermatomyositis (JDM) who presented with signs of meningismus 21 hours after the initiation of IVIG infusion. Her blood work at diagnosis showed neutrophilia and lymphopenia. The cerebrospinal fluid (CSF) analysis demonstrated neutrophilic pleocytosis, hyperproteinorrachia, and normoglycorrhachia. All microbiological tests were negative. The child fully recovered within 72 hours without neurological sequelae. IVIG-induced aseptic meningitis remains a diagnosis of exclusion. Although it is rare, pediatricians should be aware of this complication and avoid unnecessary investigations or treatment.

Keywords: pediatric rheumatology, young child, juvenile dermatomysitis, drug-induced aseptic meningitis, intravenous immunoglobulin (ivig)

Introduction

Aseptic meningitis is a known severe adverse effect of immunoglobulin. It is rare and usually resembles infectious meningitis, which makes its diagnosis challenging. Its causes are either infectious or non-infectious (also called aseptic), consisting of autoimmune, neoplasia, and iatrogenic etiologies [1].

Intravenous immunoglobulin (IVIG) is widely used for a broad range of diseases, including immunodeficiencies, neuromuscular diseases, and autoimmune diseases. The treatment of juvenile dermatomyositis (JDM) with IVIG is generally considered effective as a second-line option, particularly for steroid-resistant patients or those with predominant skin activity [2-4]. A retrospective JDM cohort in 2011 demonstrated IVIG efficacy in controlling disease activity [5]. We discuss the case of a five-and-a-half-year-old girl with JDM, who experienced no adverse events with initial IVIG (Intragam P) administration, but subsequently developed aseptic meningitis after switching to another formulary IVIG (Privigen). The possible risk factors for developing aseptic meningitis are also discussed.

This article was previously posted to the ResearchSquare preprint server in November 2021.

Case presentation

Our patient was a Chinese girl who initially presented with proximal muscle weakness and limping gait at four years of age. She also demonstrated dermatological features including heliotrope rash over the facial region and Gottron papules over her metacarpophalangeal and interphalangeal joints with cutaneous ulcerations. She had raised serum creatine kinase up to 3900 IU/L, and her MRI showed features of myositis over her bilateral shoulders, arms, and thigh muscles. She was given the diagnosis of JDM. Her Childhood Myositis Assessment Scale (CMAS) score (see the CMAS score sheet, Figure 1, in appendices) was 5/52 points (Table 1).

Table 1. Childhood Myositis Assessment Scale (CMAS) score.

Maneuver Patient score
1. Head elevation (neck flexion) 1: 1–9 seconds
2. Leg raise/touch object 0: unable to lift the leg off the table
3. Straight leg lift/duration 0: unable
4. Supine to prone 1: turns onto the side fairly easily, but cannot fully free arms and is not able to fully assume a prone position
5. Sit-ups 0: unable
6. Supine to sit 0: unable
7. Arm raise/straighten 1: can raise wrists at least up to the level of the acromioclavicular joint but not above the top of the head
8. Arm raise/duration 1: 1–9 seconds
9. Floor sit 0: unable, afraid to even try
10. All-fours maneuver 0: unable to go from a prone to an all-fours position
11. Floor rise 0: unable, even if allowed to use a chair for support
12. Chair rises 0: unable to rise from the chair, even if allowed to place hands on sides of the chair
13. Stool step 1: much difficulty. Able, but needs to place one hand on the exam table
14. Pick-up 0: unable to bend over and pick up a pencil off the floor
Open in a new tab

The patient was initially treated with intravenous methylprednisolone, subcutaneous methotrexate, and six doses of monthly IVIG (Intragam P) at presentation. The IVIG was administered at a dosage of 1 gram/kg (total of 15 grams in the volume of 250 ml) over nine hours each day for two consecutive days. She had no adverse reaction to the medication. She responded well to treatment and her muscle power improved with a CMAS of 43 out of 52 four months later. Her steroid was gradually tapered down, but she developed worsening vasculitis with necrotic lesions and chondritis over both ears. Her skin condition remained refractory despite increasing the steroid and methotrexate dosage, as well as adding oral cyclosporin A. Cyclosporin A was subsequently switched to oral cyclophosphamide. Two days after the switch, IVIG was given additionally to optimize the control of her skin activity at the age of five-and-a-half years. Due to a change in our hospital drug formulary, the patient received Privigen instead. She was given 2 grams/kg (total of 32.5 grams in the volume of 325 ml), which was infused over 11 hours.

She was asymptomatic during the infusion but developed a high fever with a temperature of 40 ºC, headache, and repeated vomiting 10 hours after the completion of the injection. She also complained of neck pain and photophobia. There was no seizure, altered state of consciousness, or abnormal behavior. Physical examination demonstrated meningismus with neck stiffness and positive Kernig sign. There was no other focal neurological deficit.

Her blood tests (Table 2) showed an elevated white cell count at 24 x 109/L with neutrophilia (absolute neutrophil count: 17.3 x 109/L), but normal C-reactive protein (<0.7 mg/L) and serum procalcitonin level (0.14 ng/ml). The CT of the brain was normal. The cerebrospinal fluid (CSF) was clear and colorless. Its analysis demonstrated neutrophilic pleocytosis with 2188 cells/mm3 (87% neutrophils) without eosinophils, hyperproteinorrachia (0.66 g/L), and normoglycorrhachia (2.9 mmol/L in CSF and 4.7 mmol/L in plasma). She was initially treated with an intravenous meningitic dose of meropenem and acyclovir. Meropenem was chosen because of the abundance of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) in the Hong Kong community [6]. The cultures from her blood sample and CSF did not isolate any causative organisms.

Table 2. Investigation results.

CSF: cerebrospinal fluid; PCR: polymerase chain reaction; DNA: deoxyribonucleic acid; RNA: ribonucleic acid

Laboratory tests Patient values Reference values
Blood tests
White cell count 24 x 109/L 5.0-15.0 x 109/L
Neutrophil count 17.3 x 109/L 1.5–8.0 x 109/L
C-reactive protein <0.7 mg/L <5.0 mg/L
Procalcitonin 0.14 ng/mL <0.5 ng/mL
The blood culture showed no growth after 5 days of incubation
First CSF results
White cell count 2188/cubic mm  
Neutrophils 87%  
Protein 0.66 g/L 0.15–0.45 g/L
Glucose 2.9 mmol/L 2.2–3.9 mmol/L
Plasma glucose 4.7 mmol/L 2.5–11.0 mmol/L
CSF PCRs of the following were negative: herpes simplex virus type 1 and type 2 DNA, varicella-zoster virus DNA and enterovirus RNA, Escherichia coli K1 DNA, Haemophilus influenzae DNA, Listeria monocytogenes DNA, Neisseria meningitidis (encapsulated) DNA, Streptococcus agalactiae DNA, Streptococcus pneumoniae DNA, cytomegalovirus DNA, human herpesvirus 6 DNA, Cryptococcus neoformans/gattii DNA
CSF showed a negative gram stain and the culture showed no growth after 7 days of incubation
CSF fungal culture showed no fungus isolated after 14 days of incubation
Second CSF results
White cell count 11/cubic mm  
Neutrophils 9%  
Protein 0.19 g/L 0.15–0.45 g/L
Glucose 3.6 mmol/L 2.2–3.9 mmol/L
Plasma glucose 5.3 mmol/L 2.5–11.0 mmol/L
Open in a new tab

A lumbar puncture was repeated on day six and CSF analysis revealed a white cell count of 11 cells/mm3 with 9% polymorphs, normal protein (0.19 g/L), and normal glucose levels (3.6 mmol/L in CSF and 5.3 mmol/L in plasma) (Table 2). The patient completed a 14-day course of meropenem. Based on the temporal relation between IVIG administration and the symptoms onset, sterile cultures, as well as the normal C-reactive protein and procalcitonin levels, a diagnosis of aseptic meningitis was made.

Her symptoms and fever subsided on day two of admission, and she recovered completely without any neurological sequelae.

Discussion

IVIG-induced aseptic meningitis is a rare complication, with an estimated incidence of 0.6-1% [7]. Apart from being used in the treatment of immune thrombocytopenia (ITP), IVIGs are also being given to patients as a treatment for various autoimmune and inflammatory diseases such as Kawasaki disease, Guillain-Barre syndrome, and chronic inflammatory demyelinating polyneuropathy. The exact pathophysiology of IVIG-induced aseptic meningitis remains unclear, with postulated mechanisms including direct toxic effect and immunological hypersensitive reaction [8].

Our patient did have the typical features of IVIG-associated aseptic meningitis described in the literature (Table 3) [7,9]. Firstly, there was a temporal relationship between the onset of the symptoms of aseptic meningitis and high-dose IVIG therapy. Secondly, the symptoms and signs of meningismus quickly resolved within 48 hours in our patient. Thirdly, although the initial bloodwork revealed leukocytosis and neutrophilia, and the CSF analysis showed neutrophilic pleocytosis, all cultures were negative. All these fit into the picture of aseptic meningitis induced by IVIG as described by Bharath et al. and Kemmotsu et al.

Table 3. Typical symptoms and signs of IVIG-induced aseptic meningitis.

IVIG: intravenous immunoglobulin; CSF: cerebrospinal fluid

  Bacterial meningitis IVIG-induced aseptic meningitis
Symptoms Headache, vomiting, photophobia, and fever
Signs Nuchal rigidity, positive Kernig sign without focal neurological sign
CSF Leukocytes/mm3 500–10,000 100–2000
Main leukocyte type Neutrophils
Other criteria Bacteria in CSF Sterile CSF; temporal relationship with IVIG infusion
Management Antibiotics Drug discontinuation; symptomatic treatment
Time to regression 7–21 days Within 2–3 days
Open in a new tab

Evidence concerning both patient and IVIG-related risk factors remains controversial. It has been suggested that a history of migraines, female sex, and underlying connective tissue disease such as systemic lupus erythematosus could be potential risk factors for developing aseptic meningitis following IVIG administration [10-12]. Further evidence is needed to evaluate whether JDM could also be a risk factor.

It is important to note that this was not the first time our patient had received IVIG. She developed aseptic meningitis after IVIG therapy was given at a higher dose (2 grams/kg) and faster rate (over 11 hours). Besides, our patient received a different brand of IVIG (Privigen) from her previous IVIG infusions (Intragam P) prior to the incidence of aseptic meningitis. Regarding IVIG-related risk factors, fast infusion rate and high initial dosage of IVIGs are thought to be risk factors for developing aseptic meningitis, but it is not always the case (Table 4). There is no concrete evidence as to whether different IVIG brands have various potentials in causing aseptic meningitis. It was thought that IgA concentration might be related. The administration of IVIG containing IgA may cause dramatic clinical reactions in patients with serum anti-IgA [1,13]. The IgA contents in both Privigen and Intragam were not specified, with Privigen stating a maximum of 0.025 mg/ml and Intragam P reporting <0.025 mg/ml (Table 5). Although 50% of patients developed aseptic meningitis after Privigen infusion in Bharath et al.'s retrospective study, due to the small number of patients, the brands of IVIG or varying commercial preparations have not been identified as risk factors.

Table 4. Documented cases of IVIG-related aseptic meningitis.

IVIG: intravenous immunoglobulin; WBC: white blood cell; CSF: cerebrospinal fluid; PEG: polyethylene glycol

  Source Number of patients Diagnosis Age (years) IVIG dose IVIG duration (hours) Brand Onset WBC x 109/L CSF CSF cytosis Treatment Time to recovery
1 Rao et al. [14] 1 Idiopathic thrombocytopenic purpura 9 0.4 g/kg 4 Sandoglobulin 12 hours after the last dose 2.5 98% Prednisone 3 mg/kg for 4 days 48 hours
2 Mitterer et al. [15] 1 Idiopathic thrombocytopenic purpura 4 0.4 g/kg Non-specified Sandoglobulin Second day 2 67% Self-limiting 2 days
3 Chaabane et al. [16] 1 Idiopathic thrombocytopenic purpura 14 0.4 g/kg Non-specified Non-specified 2 days after the last infusion 0.14 70% Floctafenine 3 days
4 Casteel-Van et al. [17] 1 Idiopathic thrombocytopenic purpura 7 0.4 g/kg 11 Sandoglobulin Third day Non-specified Non-specified Non-specified Non-specified
5 Sekul et al. [18] 1 Dystrophy 7 2 g/kg Non-specified Non-specified Within 24 hours 0.22 85% Narcotic analgesics and antiemetic agents 3–5 days
6 Kato et al. [19] 1 Idiopathic thrombocytopenic purpura 2 0.4 g/kg/day for 5 days Non-specified Prepared with PEG 7 days after therapy 0.451 9% Self-limiting 1 day
7 Casteels-Van et al. [20] 1 Idiopathic thrombocytopenic purpura 7 0.4 g/kg for 5 days 11 Sandoglobulin 1 hour after the completion of the second dose 2.45 88% Self-limiting 1 day
8 Pallares and Marshall [21] 1 Idiopathic thrombocytopenic purpura 10 1 g/kg 6 Sandoglobulin At the beginning of the second dose 2.86 97% Cefotaxime for 72 hours 2 days
9 Obando et al. [22] 2 Idiopathic thrombocytopenic purpura 6–10 1 g/kg/day for 2 days 8–12 Flebogamma 10-12 hours after the secondinfusion 0.65–7.44 60–98% Cefotaxime for <48 hours, analgesics 24–48 hours
10 Boyce and Spearman [23] 1 Kawasaki syndrome 9 2 g/kg 14 Polygam 10 hours after the last infusion 1.515 99% Ceftriaxone for 72 hours 5 days
11 Preinger-Shapiro et al. [24] 1 Acquired immune neutropenia 2 1 g/kg/day for 4 days Non-specified Sandolglobulin During the second infusion 3.5 95% Self-limiting 24 hours
12 Kressebuch et al. [25] 2 Idiopathic thrombocytopenic purpura 7–8 0.4 g/kg/day Non-specified Sandoglobulin 12 hours after the second infusion; during the third infusion 0.667–1.62 92–95% Self-limiting Within a few hours
13 Kemmotsu et al. [9] 4 Kawasaki disease 1–10 1-2 g/kg Non-specified Sulfonated/Peg-treated Within 25–40 hours from the start of the infusion 0.021–1.248 13–89% Methylprednisolone 15 mg/kg in 2 children, self-limiting in 2 children 1–2 days
14 Kaarthigeyan and Burli [26] 1 Common variable immunodeficiency 10 0.4 g/kg Non-specified Non-specified 10 days after the last infusion 0.225 Non-specified Ticarcillinclavulanate and ofloxacin Within 1 week
15 Jain et al. [27] 1 Guillain-Barre syndrome 14 0.4 g/kg/day for 5 days Non-specified Non-specified Fourth day 0.0000018 15% Hydration, analgesics 2 days
16 Vassalini et al. [28] 1 Acute Epstein-Barr virus infection 4 0.4 g/kg Non-specified Non-specified 6 hours after the second infusion 2.993 84% Ceftriaxone, dexamethasone 36 hours
17 Kattamis et al. [29] 2 Idiopathic thrombocytopenic purpura 8–11 1 g/kg/day for 2 days Non-specified Venoglobulin Non-specified 0.635–2.237 64–91% Non-specified Non-specified
Open in a new tab

Table 5. Compositions of Privigen and Intragam P.

IgG: immunoglobulin G; IgA: immunoglobulin A

  Privigen Intragam P
IgG1 67.8% 61%
lgG2 28.7% 36%
lgG3 2.3% 3%
lgG4 1.2% 1%
lgA Maximum of 0.025 mg/ml <0.025 mg/ml
Excipients L-Proline, WFI Maltose 10 mg/ml
Open in a new tab

Supportive measures such as analgesics and antiemetics seem to be sufficient in these cases [30]. Corticosteroids do not seem to be effective in treating IVIG-induced aseptic meningitis [9,10,31]. Stiehm suggested that steroids or anti-TNF could be used in severe cases of aseptic meningitis [32]. However, in Kemmotsu et al.'s study, there were no differences in the clinical courses between patients who received no medical treatment and those treated with intravenous methylprednisolone [9]. Re-infusions are not contraindicated [7,27]. In case our patient requires IVIG in the future, Privigen will be avoided. Switching to subcutaneous preparation could potentially be an effective strategy in attenuating adverse effects [33]. Subcutaneous immunoglobulin (SCIG) was associated with lower rates of aseptic meningitis [10]. Several studies have shown that SCIG can be used in treating various diseases including immunodeficiency diseases, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, etc. Further research is needed to determine its efficiency as an immunomodulatory therapy. Preventive measures including infusing at a slow rate, pre-hydration, and adequate fluid intake throughout infusion, as well as premedication with acetaminophen and antihistamine, could be considered [31].

Milder cases of aseptic meningitis might not necessarily be recognized, given that aseptic meningitis is such a rare complication of IVIG. On the other hand, post-IVIG headache is common. The true incidence of IVIG-induced aseptic meningitis could be under-reported. Although there is increasing evidence on the self-limitedness of IVIG-induced aseptic meningitis and its temporal profile, the necessity for lumbar puncture and antibiotics remains controversial [7,34]. Given that our patient had been treated with several immunomodulatory medications and her increased risks for opportunistic infections, she was treated with intravenous antibiotics.

Conclusions

IVIG-induced aseptic meningitis remains a diagnosis of exclusion. Although it is rare, pediatricians should be aware of this complication and avoid unnecessary investigations or treatment. Supportive measures seem to be sufficient in these patients. Children usually recover without neurological sequelae.

Appendices

Figure 1. Childhood Myositis Assessment Scale (CMAS) scoring sheet.

Figure 1

Open in a new tab

1. Lovell DJ, Lindsley CB, Rennebohm RM, et al.: Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum. 1999, 42:2213-2219. 10.1002/1529-0131(199910)42:10<2213::Aid-anr25>3.0.Co;2-8

2. Huber AM, Feldman BM, Rennebohm RM, et al.: Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum. 2004, 50:1595-1603. 10.1002/art.20179

The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

The authors have declared that no competing interests exist.

Human Ethics

Consent was obtained or waived by all participants in this study

References

  • 1.Drug-induced aseptic meningitis: a mini-review. Yelehe-Okouma M, Czmil-Garon J, Pape E, Petitpain N, Gillet P. Fundam Clin Pharmacol. 2018;32:252–260. doi: 10.1111/fcp.12349. [DOI] [PubMed] [Google Scholar]
  • 2.Consensus-based recommendations for the management of juvenile dermatomyositis. Bellutti Enders F, Bader-Meunier B, Baildam E, et al. Ann Rheum Dis. 2017;76:329–340. doi: 10.1136/annrheumdis-2016-209247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash. Huber AM, Kim S, Reed AM, et al. J Rheumatol. 2017;44:110–116. doi: 10.3899/jrheum.160688. [DOI] [PubMed] [Google Scholar]
  • 4.Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Huber AM, Robinson AB, Reed AM, et al. Arthritis Care Res (Hoboken) 2012;64:546–553. doi: 10.1002/acr.20695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM. Ann Rheum Dis. 2011;70:2089–2094. doi: 10.1136/ard.2011.153718. [DOI] [PubMed] [Google Scholar]
  • 6.Prevalence and associated factors for carriage of Enterobacteriaceae producing ESBLs or carbapenemase and methicillin-resistant Staphylococcus aureus in Hong Kong community. Kwok KO, Chan E, Chung PH, et al. J Infect. 2020;81:242–247. doi: 10.1016/j.jinf.2020.05.033. [DOI] [PubMed] [Google Scholar]
  • 7.Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis: a retrospective review at a single tertiary care center. Bharath V, Eckert K, Kang M, Chin-Yee IH, Hsia CC. Transfusion. 2015;55:2597–2605. doi: 10.1111/trf.13200. [DOI] [PubMed] [Google Scholar]
  • 8.The challenge of drug-induced aseptic meningitis. Moris G, Garcia-Monco JC. Arch Intern Med. 1999;159:1185–1194. doi: 10.1001/archinte.159.11.1185. [DOI] [PubMed] [Google Scholar]
  • 9.Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease. Kemmotsu Y, Nakayama T, Matsuura H, Saji T. Pediatr Rheumatol Online J. 2011;9:28. doi: 10.1186/1546-0096-9-28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Aseptic meningitis following therapy with immune globulins: a combination of product features and patient characteristics? Berg R, Fuellenhals E. Transfusion. 2016;56:3021–3028. doi: 10.1111/trf.13886. [DOI] [PubMed] [Google Scholar]
  • 11.Adverse effects of intravenous immunoglobulin therapy. Nydegger UE, Sturzenegger M. Drug Saf. 1999;21:171–185. doi: 10.2165/00002018-199921030-00003. [DOI] [PubMed] [Google Scholar]
  • 12.The challenge of drug-induced aseptic meningitis revisited. Morís G, Garcia-Monco JC. JAMA Intern Med. 2014;174:1511–1512. doi: 10.1001/jamainternmed.2014.2918. [DOI] [PubMed] [Google Scholar]
  • 13.The use of human immunoglobulins--adverse reactions. Pituch-Noworolska A, Błaut-Szlósarczyk A, Zwonarz K. https://medpress.com.pl/shop/index.php?id_product=372&controller=product&id_lang=1. Pol Merkur Lekarski. 2010;29:202–205. [PubMed] [Google Scholar]
  • 14.Intravenous immune globulin and aseptic meningitis. Rao SP, Teitlebaum J, Miller ST. Am J Dis Child. 1992;146:539–540. doi: 10.1001/archpedi.1992.02160170019004. [DOI] [PubMed] [Google Scholar]
  • 15.Two episodes of aseptic meningitis during intravenous immunoglobulin therapy of idiopathic thrombocytopenic purpura. Mitterer M, Pescosta N, Vogetseder W, Mair M, Coser P. Ann Hematol. 1993;67:151–152. doi: 10.1007/BF01701743. [DOI] [PubMed] [Google Scholar]
  • 16.Human intravenous immunoglobulin-induced aseptic meningitis: a case report. Chaabane A, Hamzaoui A, Aouam K, Klai R, Fredj NB, Boughattas NA, Mahjoub S. J Clin Pharmacol. 2012;52:279–281. doi: 10.1177/0091270010394183. [DOI] [PubMed] [Google Scholar]
  • 17.Aseptic meningitis associated with high dose intravenous immunoglobulin therapy. Casteels-Van Daele M, Wijndaele L, Brock P, Kruger M, Gillis P. J Neurol Neurosurg Psychiatry. 1992;55:980–981. doi: 10.1136/jnnp.55.10.980-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Sekul EA, Cupler EJ, Dalakas MC. Ann Intern Med. 1994;121:259–262. doi: 10.7326/0003-4819-121-4-199408150-00004. [DOI] [PubMed] [Google Scholar]
  • 19.Administration of immune globulin associated with aseptic meningitis. Kato E, Shindo S, Eto Y, Hashimoto N, Yamamoto M, Sakata Y, Hiyoshi Y. https://pubmed.ncbi.nlm.nih.gov/2453686/ JAMA. 1988;259:3269–3271. [PubMed] [Google Scholar]
  • 20.Intravenous immune globulin and acute aseptic meningitis. Casteels-Van Daele M, Wijndaele L, Hanninck K, Gillis P. https://pubmed.ncbi.nlm.nih.gov/2381452/ N Engl J Med. 1990;323:614–615. [PubMed] [Google Scholar]
  • 21.Acute aseptic meningitis associated with administration of intravenous immune globulin. Pallares DE, Marshall GS. Am J Pediatr Hematol Oncol. 1992;14:279. doi: 10.1097/00043426-199208000-00019. [DOI] [PubMed] [Google Scholar]
  • 22.Aseptic meningitis due to administration of intravenous immunoglobulin with an unusually high number of leukocytes in cerebrospinal fluid. Obando I, Duran I, Martin-Rosa L, Cano JM, Garcia-Martin FJ. Pediatr Emerg Care. 2002;18:429–432. doi: 10.1097/00006565-200212000-00006. [DOI] [PubMed] [Google Scholar]
  • 23.Acute aseptic meningitis secondary to intravenous immunoglobulin in a patient with Kawasaki syndrome. Boyce TG, Spearman P. Pediatr Infect Dis J. 1998;17:1054–1056. doi: 10.1097/00006454-199811000-00023. [DOI] [PubMed] [Google Scholar]
  • 24.Aseptic meningitis: a frequent side-effect of intravenous immunoglobulin? Preminger-Shapiro R, Nussinovitch M, Soen G, Varsano I. Eur J Pediatr. 1995;154:866–867. doi: 10.1007/BF01959803. [DOI] [PubMed] [Google Scholar]
  • 25.Cerebrospinal fluid inflammation induced by intravenous immunoglobulins. Kressebuch H, Schaad UB, Hirt A, Bianchetti MG. Pediatr Infect Dis J. 1992;11:894–895. doi: 10.1097/00006454-199210000-00020. [DOI] [PubMed] [Google Scholar]
  • 26.Aseptic meningitis following intravenous immunoglobulin therapy of common variable immunodeficiency. Kaarthigeyan K, Burli VV. J Pediatr Neurosci. 2011;6:160–161. doi: 10.4103/1817-1745.92858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Acute aseptic meningitis due to intravenous immunoglobulin therapy in Guillain-Barré syndrome. Jain RS, Kumar S, Aggarwal R, Kookna JC. Oxf Med Case Reports. 2014;2014:132–134. doi: 10.1093/omcr/omu051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Aseptic meningitis induced by intravenous immunoglobulins in a child with acute Epstein-Barr virus infection and thrombocytopenia. Vassalini P, Ajassa C, Di Ruscio V, et al. https://www.infezmed.it/media/journal/Vol_27_2_2019_14.pdf. Infez Med. 2019;27:194–197. [PubMed] [Google Scholar]
  • 29.Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenously administered immunoglobulin G. Kattamis AC, Shankar S, Cohen AR. J Pediatr. 1997;130:281–283. doi: 10.1016/s0022-3476(97)70355-x. [DOI] [PubMed] [Google Scholar]
  • 30.Intravenous immunoglobulin-induced aseptic meningitis-a narrative review of the diagnostic process, pathogenesis, preventative measures and treatment. Kretowska-Grunwald A, Krawczuk-Rybak M, Sawicka-Zukowska M. J Clin Med. 2022;11:1–5. doi: 10.3390/jcm11133571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Cherin P, Marie I, Michallet M, et al. Autoimmun Rev. 2016;15:71–81. doi: 10.1016/j.autrev.2015.09.002. [DOI] [PubMed] [Google Scholar]
  • 32.Adverse effects of human immunoglobulin therapy. Stiehm ER. Transfus Med Rev. 2013;27:171–178. doi: 10.1016/j.tmrv.2013.05.004. [DOI] [PubMed] [Google Scholar]
  • 33.Adverse effects of immunoglobulin therapy. Guo Y, Tian X, Wang X, Xiao Z. Front Immunol. 2018;9:1299. doi: 10.3389/fimmu.2018.01299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Meningitis and skin reaction after intravenous immune globulin therapy. Gabor EP. Ann Intern Med. 1997;127:1130. doi: 10.7326/0003-4819-127-12-199712150-00020. [DOI] [PubMed] [Google Scholar]

Articles from Cureus are provided here courtesy of Cureus Inc.

RESOURCES